Fruzaqla is a once-daily oral treatment for metastatic colorectal cancer in adults who have already tried other therapies. It inhibits VEGF receptors to slow tumor growth and improve survival.
To Get Full Access :
To Get Full Access :
Fruzaqla is a once-daily oral treatment for metastatic colorectal cancer in adults who have already tried other therapies. It inhibits VEGF receptors to slow tumor growth and improve survival.
Supported 1000+ clinical trials globally
Provides services across regulatory, legal & clinical research
Unmatched intelligence on batches, expiry, spacing, and historical data from innovators
Integrated CRO services as part of our offerings
Insights on global pricing for smarter clinical trial supply decisions
Global sourcing capability across US, EU, South Africa, Canada, Japan, Australia, New Zealand, Southeast Asia, and other key markets
For full access Sign-up / Sign-in using below Methods:
By continuing, you agree to our Terms & Conditions and Privacy Policy. You can review them anytime.
